Table 1 Clinical characteristics of 181 patients with CRO infections
From: Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections
Characteristic | Findings |
|---|---|
Age (year), mean ± SD | 0.39 ± 0.17 |
Male, n (%) | 135 (76.2) |
APACHE II score, mean ± SD | 19.25 ± 6.11 |
Distribution of departments, n (%) | |
Hematology department | 111 (61.3) |
ICU | 58 (32.0) |
Other departments | 12 (6.6) |
Comorbidities, n (%) | |
Chronic heart failure | 52 (28.7) |
Diabetes mellitus | 45 (24.9) |
COPD | 34 (18.8) |
Chronic kidney disease | 31 (17.7) |
Immunosuppressive status | 25 (13.8) |
Complications, n (%) | |
Shock | 42 (23.2) |
MODS | 40 (22.1) |
ARDS | 27 (14.9) |
Infection types, n (%) | |
Pneumonia | 104 (57.5) |
Bloodstream infection | 36 (19.9) |
Intestinal infection | 35 (19.3) |
Abdominal infection | 9 (5.0) |
Other infections | 40 (22.1) |
Multiple site infections | 64 (35.4) |
Responsible pathogens, n (%) | |
K.P | 91 (50.3) |
P.A | 58 (32.0) |
E. coli | 16 (8.8) |
A.B | 12 (6.6) |
Multiple bacterial infections | 50 (27.6) |
Polymyxin B dose, mean ± SD | 1.91 ± 0.33 |
Initial treatment, n (%) | 70 (38.7) |
Duration of polymyxin B treatment, days, median (IQR) | 11 (6, 19) |
Antibiotic combination, n (%) | 167 (92.3) |
Microbiological eradication, n (%) | 76 (42.0) |